

## H2020-ITN THERACAT (765497)

<b>Work Package Number</b>	WP1	<b>Task Number</b>	N/A	<b>Deliverable Number</b>	D1.3	<b>Lead Beneficiary</b>	IBEC
<b>Deliverable Title</b>	HCT – Requirement No. 3						
<b>Contractual Delivery Date</b>	28/02/2019	<b>Nature</b>	Ethics			<b>Dissemination Level</b>	CO
<b>Actual Delivery Date</b>	18/03/2019	<b>Contributors</b>	IBEC and all Beneficiaries				

### Overview/Abstract

In case of use of human cells/tissues available commercially, details on cells/tissues type and provider must be submitted.

### Explanation for large delay in submitting deliverable

N/A

### Led by

<b>Name</b>	Rosa Miralles	<b>Partner</b>	IBEC	<b>Date</b>	27/02/2019
-------------	---------------	----------------	------	-------------	------------

### Reviewed by

<b>Name</b>	Lorenzo Albertazzi	<b>Partner</b>	IBEC	<b>Date</b>	13/03/2019
<b>Name</b>	Anja Palmans	<b>Partner</b>	TUE	<b>Date</b>	04/03/2019
<b>Name</b>	Thomas Ward	<b>Partner</b>	BAS	<b>Date</b>	01/03/2019
<b>Name</b>	Asier Unciti-Broceta	<b>Partner</b>	EDI	<b>Date</b>	02/03/2019
<b>Name</b>	Laura Goldie	<b>Partner</b>	BGX	<b>Date</b>	13/03/2019
<b>Name</b>	Ronit Satchi-Fainaro	<b>Partner</b>	TAU	<b>Date</b>	18/03/2019
<b>Name</b>	Marc Robillard	<b>Partner</b>	TAG	<b>Date</b>	13/03/2019

### Document Control

<b>Issue #</b>	<b>Date</b>	<b>Changed Pages</b>	<b>Cause of Change</b>	<b>Implemented by</b>
1	01/03/2019	3	Update of the human cells to be used in the framework of the project by partner BAS.	Thomas Ward (BAS)

2	02/03/2019	3	Update of the human cells to be used in the framework of the project by partner EDI.	Asier Unciti-Broceta (EDI)
3	13/03/2019	3	Update of the human cells to be used in the framework of the project by partner BGX.	Laura Goldie (BGX)
4	13/03/2019	4	Update of the human cells to be used in the framework of the project by partner TAG.	Marc Robillard (TAG)
5	18/03/2019	4	Update of the human cells to be used in the framework of the project by partner TAU.	Ronit Satchi-Fainaro (TAU)

---

## 1. HCT – Requirement No. 3

The samples of human origin to be used in this project are cells that are commercially available. In particular, human cells that are planned to be used in the THERACAT project are detailed below:

### IBEC, TUE:

- PC-3 (ATCC® CRL-1435™): <https://www.lgcstandards-atcc.org/products/all/CRL-1435.aspx>
- HeLa (ATCC® CCL-2™): <https://www.lgcstandards-atcc.org/products/all/CCL-2.aspx>
- LNCaP (ATCC® CRL-1740™): <http://www.lgcstandards-atcc.org/Products/All/CRL-1740.aspx>
- MCF7 (ATCC® HTB-22™): <https://www.lgcstandards-atcc.org/products/all/HTB-22.aspx>

### BAS:

- HeLa (ATCC® CCL-2™): <https://www.lgcstandards-atcc.org/products/all/CCL-2.aspx>
- RCC4 plus vector alone (ECACC 03112702): [https://www.phe-culturecollections.org.uk/products/celllines/generalcell/detail.jsp?refId=03112702&collection=ecacc\\_gc](https://www.phe-culturecollections.org.uk/products/celllines/generalcell/detail.jsp?refId=03112702&collection=ecacc_gc)
- RCC4plusVHL (ECACC 03112703): [https://www.phe-culturecollections.org.uk/products/celllines/generalcell/detail.jsp?refId=03112703&collection=ecacc\\_gc](https://www.phe-culturecollections.org.uk/products/celllines/generalcell/detail.jsp?refId=03112703&collection=ecacc_gc)

### EDI, BGX:

- PC-3 (ATCC® CRL-1435™): <https://www.lgcstandards-atcc.org/products/all/CRL-1435.aspx>
- LNCaP (ATCC® CRL-1740™): <http://www.lgcstandards-atcc.org/Products/All/CRL-1740.aspx>
- MCF7 (ATCC® HTB-22™): <https://www.lgcstandards-atcc.org/products/all/HTB-22.aspx>
- MDA-MB-231 (ATCC® HTB-26™): <https://www.lgcstandards-atcc.org/products/all/HTB-26.aspx>
- HCT116 (ATCC® CCL-247™): <http://www.lgcstandards-atcc.org/en/Products/All/CCL-247.aspx>
- A549 (ATCC® CCL-185™): <https://www.lgcstandards-atcc.org/Products/All/CCL-185.aspx>
- A375 (ATCC® CRL-1619™): <https://www.lgcstandards-atcc.org/Products/All/CRL-1619.aspx>
- OVCAR3 (ATCC® HTB-161™): <https://www.lgcstandards-atcc.org/Products/All/HTB-161.aspx>
- MCF 10A (ATCC® CRL-10317™): <https://www.lgcstandards-atcc.org/products/all/CRL-10317.aspx>

**TAU:**

- MDA-MB-231 (ATCC® HTB-26™): <https://www.lgcstandards-atcc.org/products/all/HTB-26.aspx>
- MDA-MB-436 (ATCC® HTB-130™): <https://www.lgcstandards-atcc.org/products/all/HTB-130.aspx>
- MDA-MB-361 (ATCC® HTB-27™): <https://www.lgcstandards-atcc.org/products/all/HTB-27.aspx>
- MCF7 (ATCC® HTB-22™): <https://www.lgcstandards-atcc.org/products/all/HTB-22.aspx>
- MIA PaCa-2 (ATCC® CRL-1420™): <https://www.lgcstandards-atcc.org/products/all/CRL-1420.aspx>
- PANC-1 (ATCC® CRL-1469™): <https://www.lgcstandards-atcc.org/products/all/CRL-1469.aspx>
- Panc 02.03 (ATCC® CRL-2553™): <https://www.lgcstandards-atcc.org/products/all/CRL-2553.aspx>
- BxPC-3 (ATCC® CRL-1687™): <https://www.lgcstandards-atcc.org/products/all/CRL-1687.aspx>
- A375 (ATCC® CRL-1619™): <https://www.lgcstandards-atcc.org/Products/All/CRL-1619.aspx>

**TAG:**

- LS 174T (ATCC® CL-188™): <https://www.lgcstandards-atcc.org/Products/All/CL-188.aspx>
- Capan-1 (ATCC® HTB-79™): <https://www.lgcstandards-atcc.org/Products/All/HTB-79.aspx>
- OVCAR3 (ATCC® HTB-161™): <https://www.lgcstandards-atcc.org/Products/All/HTB-161.aspx>
- MCF7 (ATCC® HTB-22™): <https://www.lgcstandards-atcc.org/products/all/HTB-22.aspx>
- BT-20 (ATCC® HTB-19™): <https://www.lgcstandards-atcc.org/products/all/HTB-19.aspx>

The project does not plan to use human embryonic stem cells, human cloning, or procedures where humans could be involved at all.

## 2. References

N/A